TY - JOUR
T1 - Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery
AU - Li, Xiaojian
AU - Vogt, Frederick G.
AU - Hayes, Don
AU - Mansour, Heidi M.
N1 - Funding Information:
The authors gratefully acknowledge fellowship support from the UK Center of Membrane Sciences, the Graduate School Academic Year Fellowship and the Daniel R. Reedy Quality Achievement Fellowship awarded to Xiaojian Li. The authors thank Dr. Dicky Sick Ki Yu for SEM access, Dr. Tonglei Li for XRPD and HSM access, and Dr. Hilt for ATR-FTIR access at the University of Kentucky.
PY - 2014/2/14
Y1 - 2014/2/14
N2 - The purpose of this study was to systematically design pure antibiotic drug dry powder inhalers (DPIs) for targeted antibiotic pulmonary delivery in the treatment of pulmonary infections and comprehensively correlate the physicochemical properties in the solid-state and spray-drying conditions effects on aerosol dispersion performance as dry powder inhalers (DPIs). The two rationally chosen model antibiotic drugs, tobramycin (TOB) and azithromycin (AZI), represent two different antibiotic drug classes of aminoglycosides and macrolides, respectively. The particle size distributions were narrow, unimodal, and in the microparticulate/nanoparticulate size range. The SD particles possessed relatively spherical particle morphology, smooth surface morphology, low residual water content, and the absence of long-range molecular order. The emitted dose (ED%), fine particle fraction (FPF%) and respirable fraction (RF%) were all excellent. The MMAD values were in the inhalable range (<10 μm) with smaller MMAD values for SD AZI powders in contrast to SD TOB powders. Positive linear correlations were observed between the aerosol dispersion performance parameter of FPF with increasing spray-drying pump rates and also with the difference between thermal parameters expressed as Tg - To (i.e. the difference between the glass transition temperature and outlet temperature) for SD AZI powders. The aerosol dispersion performance for SD TOB appeared to be influenced by its high water vapor sorption behavior (hygroscopicity) and pump rates or To. Aerosol dispersion performance of SD powders were distinct for both antibiotic drug aerosol systems and also between different pump rates for each system.
AB - The purpose of this study was to systematically design pure antibiotic drug dry powder inhalers (DPIs) for targeted antibiotic pulmonary delivery in the treatment of pulmonary infections and comprehensively correlate the physicochemical properties in the solid-state and spray-drying conditions effects on aerosol dispersion performance as dry powder inhalers (DPIs). The two rationally chosen model antibiotic drugs, tobramycin (TOB) and azithromycin (AZI), represent two different antibiotic drug classes of aminoglycosides and macrolides, respectively. The particle size distributions were narrow, unimodal, and in the microparticulate/nanoparticulate size range. The SD particles possessed relatively spherical particle morphology, smooth surface morphology, low residual water content, and the absence of long-range molecular order. The emitted dose (ED%), fine particle fraction (FPF%) and respirable fraction (RF%) were all excellent. The MMAD values were in the inhalable range (<10 μm) with smaller MMAD values for SD AZI powders in contrast to SD TOB powders. Positive linear correlations were observed between the aerosol dispersion performance parameter of FPF with increasing spray-drying pump rates and also with the difference between thermal parameters expressed as Tg - To (i.e. the difference between the glass transition temperature and outlet temperature) for SD AZI powders. The aerosol dispersion performance for SD TOB appeared to be influenced by its high water vapor sorption behavior (hygroscopicity) and pump rates or To. Aerosol dispersion performance of SD powders were distinct for both antibiotic drug aerosol systems and also between different pump rates for each system.
KW - Aerosol dispersion performance modeling
KW - Cystic fibrosis
KW - Dry powder inhalers (DPIs)
KW - Glass transition
KW - Pulmonary infections
KW - Respiratory delivery
UR - http://www.scopus.com/inward/record.url?scp=84890522240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890522240&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2013.10.016
DO - 10.1016/j.ejps.2013.10.016
M3 - Article
C2 - 24215736
AN - SCOPUS:84890522240
SN - 0928-0987
VL - 52
SP - 191
EP - 205
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
IS - 1
ER -